Navigation Links
Varian Medical Systems Books $77 Million Order to Equip Proton Treatment Center in Saudi Arabia
Date:1/26/2012

PALO ALTO, Calif., Jan. 26, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has booked a $77 million order with Saudi Particle Therapy Centre LLC to equip a new proton therapy facility at the King Fahd Medical Center in Riyadh, Saudi Arabia. Varian will equip the new center with a ProBeam™ system for five treatment rooms as well as two TrueBeam™ medical linear accelerators. Equipment delivery and installation is expected to commence in spring 2013 and patient treatments are scheduled to begin in late 2014. The agreement will also include a multi-year service contract that should commence as the installation is completed.

"We are honored to have been selected to supply our equipment and software for this prestigious new facility, which will make life-saving proton therapy treatments available for the first time to cancer patients in this region," says Tim Guertin, Varian's chief executive officer. "This is an exciting step forward for our Varian Particle Therapy business."

Proton therapy makes it possible to treat certain types of cancer more precisely and with potentially fewer side effects than with conventional radiation therapy. With proton therapy, the risk of damage to healthy tissues is reduced. The method can be applied for many of the most common types of cancer and offers advantages when treating tumors close to radiosensitive tissues. In pediatric patients the risk of developing a new, radiation-induced cancer later in life can be reduced.

"We believe that more and more proton centers will want to employ the full suite of Varian products and technology for radiotherapy and radiosurgery as well as particle therapy for world-class cancer treatments," said Guertin.  "The combination of these technologies based on 60 years of innovation puts Varian in a unique position to help advance clinical care for patients around the world." 

Varian is currently installing and commissioning its ProBeam system at the Scripps Proton Center near San Diego.  The company has also been selected to provide equipment for new proton therapy centers at the University of Maryland and in Mestre, Italy.  It has been identified as the preferred provider for a new center at Emory University near Atlanta.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

 

 


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... ... 18, 2019 , ... “Impact of the Biofield Energy Healing ... has been named No. 1 International Best Seller and Hot New Release on ... and Theory, and Mind-Body Connection in the USA, Canada, United Kingdom, and Australia. ...
(Date:11/19/2019)... ... November 19, 2019 , ... HashCash Consultants is going to ... part of a genome research initiative for precision drugs. , The collaboration is expected ... that patients and contributors have more control over their genome records and the way ...
(Date:11/16/2019)... , ... November 16, 2019 , ... International Splash Awards ... Tools and Apps category. , Srijan got nominated for its efforts at the ... commendable work for Estee Lauder under tools and apps category. The event was organized ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... November 15, 2019 , ... ... United States, access to cannabis via well-managed dispensaries becomes more and more important, ... Plans, industry-leading online provider of state-of-the-art, online, custom cannabis business plans is now ...
(Date:11/15/2019)... ... November 15, 2019 , ... Spectrum ... Newsday’s Top Long Island Workplaces for 2019. The recently announced rankings honor those ... process, Newsday worked in partnership with Energage to conduct surveys into organizational health ...
(Date:11/14/2019)... ... 2019 , ... EMulate Therapeutics, Inc., a clinical-stage therapeutic device ... have 5 poster presentations related to its medical devices for treating adult and ... in Phoenix, beginning on November 20 . , Two posters will ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... individuals/organizations who have truly impacted those diagnosed with infertility. This year, Academy of ... Award for Achievement, presented at the Night of Hope Gala in New York ...
(Date:11/12/2019)... ... 2019 , ... Raintree Rehab, a division of Raintree Systems ... operators throughout the United States and Physitrack, an Apple Mobility Partner and world ... joint venture to develop and market clinical outcomes data solutions. , Both companies ...
Breaking Medicine News(10 mins):